The downgrade from Overweight to Neutral by a major financial institution like JP Morgan, coupled with a drastic reduction in the price target, is likely to negatively impact investor sentiment and the short-term stock price of Biomea Fusion. Such a significant adjustment in both rating and price target reflects a change in the bank's outlook on the company, potentially due to underlying challenges or revised expectations that could deter investors.